Dihexa Research: Cognitive Enhancement and Angiotensin IV Analog Mechanism

# Dihexa Research: Cognitive Enhancement and Angiotensin IV Analog Mechanism

For research purposes only. Not for human use. Dihexa has never entered human clinical trials; every finding described below is preclinical.

Introduction

Dihexa (N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide) is an orally active, blood-brain-barrier-penetrant small-molecule peptide derivative developed at Washington State University (WSU) as a cognitive-enhancement candidate. It descends from angiotensin IV (AngIV), a hexapeptide fragment of the renin-angiotensin system that unexpectedly showed procognitive activity in animal studies during the 1990s.

Dihexa deserves an unusually careful evidence review — not because the science is unimportant, but because its literature has been directly affected by a 2025 retraction of its key mechanism paper. An accurate account of what remains standing, and what does not, is exactly what researchers evaluating this compound need. Supplier listings are on the dihexa comparison page.

Background: From Angiotensin IV to Dihexa

The AngIV research program at WSU, led by Joseph Harding and John Wright, observed over two decades that AngIV-related peptides facilitate learning and memory in rodent models. A systematic review of experimental studies of angiotensin IV and angiotensin-(1-7) across the cognition literature summarizes this body of work (Neuroscience & Biobehavioral Reviews, 2018; PMID: 29733881).

Native AngIV has two fatal drug-development flaws: a plasma half-life measured in seconds and no meaningful blood-brain-barrier penetration. The WSU group therefore synthesized metabolically stabilized analogs, culminating in dihexa.

Structure and Pharmacological Rationale

Dihexa's design lineage runs through Norleucine¹-AngIV (Nle¹-AngIV), a stabilized hexapeptide analog that retained AngIV's procognitive activity in rodent work but still could not survive oral administration or cross the blood-brain barrier efficiently. Dihexa strips the molecule down further: an N-terminal hexanoic acid cap replaces charged residues to add lipophilicity, the core is reduced to a Tyr-Ile dipeptide, and a 6-aminohexanoic amide tail replaces the C-terminal residues. The result behaves less like a peptide and more like a small molecule — orally absorbable, metabolically stable, and brain-penetrant, at least as reported in the originating lab's characterization (PMID: 23055539).

One more piece of background matters for interpreting this literature. The "AT4 receptor" that AngIV binds was identified in the early 2000s as insulin-regulated aminopeptidase (IRAP), an enzyme abundant in brain regions involved in memory. For years the field debated whether AngIV analogs work by inhibiting IRAP's peptidase activity or through some other target; the WSU group's HGF/c-Met hypothesis was a proposed resolution of that puzzle. With the c-Met paper now retracted, the actual molecular target through which dihexa produces its reported behavioral effects must be regarded as an open question — IRAP inhibition, HGF-system modulation, and off-target effects all remain on the table.

McCoy et al., 2013 — Journal of Pharmacology and Experimental Therapeutics (PMID: 23055539). This paper introduced dihexa: in scopolamine-impaired and aged rats, orally administered dihexa improved performance in the Morris water maze spatial-learning task. The compound was reported to be orally bioavailable and brain-penetrant — the properties that made it notable. Readers should know this paper received a formal Expression of Concern from the journal in 2021, which remains unresolved on the record.

The Proposed Mechanism — and Its Retraction

For a decade, dihexa's proposed mechanism was potentiation of hepatocyte growth factor (HGF) signaling through the c-Met receptor, driving hippocampal synaptogenesis.

Benoist et al., 2014 — JPET. This was the central mechanistic paper: it reported that dihexa binds HGF with high affinity, potentiates c-Met phosphorylation at subthreshold HGF concentrations, induces hippocampal spinogenesis and synaptogenesis, and that an HGF antagonist blocks dihexa's cognitive effects. This paper was formally retracted by JPET in April 2025 (Retraction: J Pharmacol Exp Ther. 2025;392(4):103567), following a 2021 Expression of Concern.

The retraction does not by itself prove the HGF/c-Met hypothesis false — but it removes the primary experimental support for it from the literature. Reviews built on that foundation, including the WSU group's own development review of AngIV analogs for Alzheimer's and Parkinson's disease (Progress in Neurobiology, 2015; PMID: 25455861) and their proposal of the brain HGF/c-Met system as an Alzheimer's target (Journal of Alzheimer's Disease, 2015; PMID: 25649658), must now be read with that context.

What Independent Evidence Remains

The most meaningful post-retraction question is: has any group outside the originating lab reproduced dihexa's effects? Two independent animal studies are indexed:

APP/PS1 Alzheimer's-model mice, 2021 — Brain Sciences (PMID: 34827486). An independent group reported that dihexa rescued cognitive impairment and recovered memory in the APP/PS1 transgenic mouse via PI3K/AKT signaling — a partially different mechanistic account than the retracted HGF/c-Met work, though in the same growth-factor signaling family.

Huntington's-model rats, 2024 — Journal of Huntington's Disease (PMID: 38489193). An angiotensin IV analog was tested against 3-nitropropionic acid-induced Huntington's-like symptoms in rats, reporting protective effects on motor and cognitive endpoints.

These studies keep the underlying pharmacology plausible, but two animal papers are a thin replication base for a compound whose foundational mechanism paper was retracted.

It is also worth understanding what the behavioral evidence actually measures. The Morris water maze — the workhorse assay across the dihexa literature — places a rodent in a pool of opaque water with a hidden escape platform; over repeated trials, declining escape latency indexes spatial learning, and probe trials without the platform index memory retention. It is a legitimate, decades-validated assay, but it measures hippocampal spatial learning in rodents, full stop. Translating water-maze gains in scopolamine-impaired rats into claims about human memory, focus, or "cognitive enhancement" skips every intermediate step of drug development — dose-ranging, pharmacokinetics in humans, safety, and cognitive endpoints validated for people. For dihexa, every one of those steps remains untaken.

The Human Evidence: None

This must be stated plainly:

• •Zero human clinical trials of dihexa have been published or registered — no safety, tolerability, pharmacokinetic, or efficacy data in humans exist
• •All cognitive findings come from rodent models (water maze and related tasks)
• •No long-term animal toxicology has been published
• •A theoretical oncology concern follows from the mechanism itself: HGF/c-Met is a well-known oncogenic signaling axis, and c-Met activation is implicated in multiple cancers. A compound designed to potentiate this pathway carries an unquantified, unstudied long-term proliferative risk

Evidence Quality Assessment

Among the peptides commonly discussed in cognitive-enhancement research, dihexa has the widest gap between online enthusiasm and published evidence. Compare this with Semax, which — whatever its methodological limitations — at least has decades of human clinical use documented in Russian medicine.

Research Tools

Researchers comparing nootropic candidates can consult the dihexa price comparison page, the broader nootropic peptide comparison, and the peptide calculator for solution preparation math.

FAQ

Was the main dihexa paper really retracted?

Yes. The 2014 JPET paper establishing the HGF/c-Met mechanism was retracted in April 2025, after a 2021 Expression of Concern. The 2013 paper introducing dihexa (PMID: 23055539) carries its own unresolved Expression of Concern.

Does the retraction mean dihexa doesn't work?

Not necessarily — it means the primary evidence for its proposed mechanism is no longer citable support. Two independent animal studies (s: 34827486, 38489193) report cognitive benefits, but no human data exist at all.

Has dihexa been tested in humans?

No. There are no published or registered human trials of dihexa of any kind — no first-in-human safety study, no pharmacokinetic characterization, and no cognitive efficacy trial. Any dosing figures circulating in research communities are extrapolations from rodent studies, not measured human data.

Why is the HGF/c-Met mechanism a safety question?

c-Met is an oncogenic receptor; chronic pharmacological potentiation of growth-factor signaling raises a theoretical cancer-risk concern that has never been studied for dihexa.

References

1. McCoy AT, et al. Evaluation of metabolically stabilized angiotensin IV analogs as procognitive/antidementia agents. J Pharmacol Exp Ther. 2013. PMID: 23055539 (Expression of Concern, 2021)

2. Wright JW, Harding JW. The development of small molecule angiotensin IV analogs to treat Alzheimer's and Parkinson's diseases. Prog Neurobiol. 2015. PMID: 25455861

3. Wright JW, et al. The brain hepatocyte growth factor/c-Met receptor system: a new target for the treatment of Alzheimer's disease. J Alzheimers Dis. 2015. PMID: 25649658

4. Cognitive benefits of angiotensin IV and angiotensin-(1-7): a systematic review of experimental studies. Neurosci Biobehav Rev. 2018. PMID: 29733881

5. AngIV-analog dihexa rescues cognitive impairment and recovers memory in the APP/PS1 mouse via the PI3K/AKT signaling pathway. Brain Sci. 2021. PMID: 34827486

6. Effects of an angiotensin IV analog on 3-nitropropionic acid-induced Huntington's disease-like symptoms in rats. J Huntingtons Dis. 2024. PMID: 38489193

---

This article is for informational and research purposes only. Dihexa research materials are not for human consumption.